FOLH1 and prostate cancer: In contrast, the more recently FDA-approved prostate-specific membrane antigen (PSMA)-targeted PET radioligand, [18F]DCFPyL (Pylarify®), proved to be highly selective for PSMA-positive tumor cells and as such, provide high accuracy for the detection of PSMA-positive lesions in men with prostate cancer.